Archives | Selexis SA

January 09, 2019

Selexis Expands Strategic Immuno-Oncology Alliance with Agenus

January 04, 2019

Selexis SA to Participate at Several Upcoming Industry Conferences

December 17, 2018

Teneobio and Selexis Enter Second Services Agreement to Develop Research Cell Banks as Teneobio Prepares to Advance Three Additional Oncology-Targeting Multi-Specific UniAbs into the Clinic

December 03, 2018

KBI Biopharma Inc. and Selexis SA Form Joint Scientific Advisory Board

October 18, 2018

Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 100 drug products in clinical development and the manufacture of four commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to industry.